THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [10.17]-C124 ID: TIP-MED-000394 ⚠️ HIGH-ALERT / SPECIALIST SUPERVISION

Coenzyme Q10 (Ubidecarenone)

Active Ingredient / Scientific Identity: Coenzyme Q10 • Class: Mitochondrial Metabolic Coenzymes & Neuropathic/Myopathic Antioxidants (Schedule H / Nutraceutical)

⚖️ Compare Profile
Generic / Entity NameCoenzyme Q10 (Ubidecarenone) ([10.17]-C124)
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassMitochondrial Metabolic Coenzymes & Neuropathic/Myopathic Antioxidants (Schedule H / Nutra
Available Dosage FormsAlpha-Lipoic Acid Tablets/Capsules: 100 mg, 300 mg, 600 mg. Coenzyme Q10 Softgels: 100 mg, 200 mg, 300 mg. L-C
Regulatory ClassificationNon-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommend
Key Warning & Review DateRenal: Safe (in haemodialysis, IV L-Carnitine post-dialysis or low-dose oral 500 mg is preferred). Hepatic: Safe (L-Carnitine
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Non-Schedule / OTC or Schedule K Permitted Preparati🚨 Clinically High-Alert: Independent Dose & Route Verification Required☣️ Hazardous / Reproductive Precaution: Strict Handling & Contraception Protocol

1. Clinical & Scientific Overview

Coenzyme Q10 (Ubidecarenone) (TIP-MED-000394, Reference Code [10.17]-C124) is classified under Vitamins, Minerals & Nutritional Supplements (Ch 10) as a Mitochondrial Metabolic Coenzymes & Neuropathic/Myopathic Antioxidants (Schedule H / Nutraceutical). Within the Indian regulatory and compendial framework, it is governed under Non-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommended for High-Dose/Therapeutic Regimens).

Verified Indian Market Examples / Compendial Status:
Co-indexed constituent under primary monograph [10.17] (Alpha-Lipoic Acid, Coenzyme Q10 (Ubidecarenone) & L-Carnitine). Representative Indian Market Examples (Edition 2.7 Ch 10 [10.17], p. 135): Alpha-Lipoic Acid (ALA): Ala (100/300/600 mg), Thioctacid; FDCs with Methylcobalamin + Pregabalin/Benfotiamine (Nurokind-Plus, Meconeuron OD). Coenzyme Q10: CoQ (100/300 mg), Ubicar. L-Carnitine: Carnitor (500 mg PO / 1 g IV), Evion-LC — Strengths & Dosage Forms: Alpha-Lipoic Acid Tablets/Capsules: 100 mg, 300 mg, 600 mg. Coenzyme Q10 Softgels: 100 mg, 200 mg, 300 mg. L-Carnitine Tablets: 500 mg; Oral Solution: 500 mg/5mL; IV: 1 g/5mL
Co-indexed constituent under primary monograph [10.17] (Alpha-Lipoic Acid, Coenzyme Q10 (Ubidecarenone) & L-Carnitine). Representative Indian Market Examples (Edition 2.7 Ch 10 [10.17], p. 135): Alpha-Lipoic Acid (ALA): Ala (100/300/600 mg), Thioctacid; FDCs with Methylcobalamin + Pregabalin/Benfotiamine (Nurokind-Plus, Meconeuron OD). Coenzyme Q10: CoQ (100/300 mg), Ubicar. L-Carnitine: Carnitor (500 mg PO / 1 g IV), Evion-LC — Strengths & Dosage Forms: Alpha-Lipoic Acid Tablets/Capsules: 100 mg, 300 mg, 600 mg. Coenzyme Q10 Softgels: 100 mg, 200 mg, 300 mg. L-Carnitine Tablets: 500 mg; Oral Solution: 500 mg/5mL; IV: 1 g/5mL
Dosage Forms & Available Strengths:
Alpha-Lipoic Acid Tablets/Capsules: 100 mg, 300 mg, 600 mg. Coenzyme Q10 Softgels: 100 mg, 200 mg, 300 mg. L-Carnitine Tablets: 500 mg; Oral Solution: 500 mg/5mL; IV: 1 g/5mL
Routes: Oral / Parenteral / Topical per formulation

3. Mechanism of Action & Pharmacodynamics

Mitochondrial Metabolic Coenzymes & Neuropathic/Myopathic Antioxidants (Schedule H / Nutraceutical) acting on target receptor/enzyme pathways in Vitamins, Minerals & Nutritional Supplements (Ch 10): clinical efficacy is mediated via Mitochondrial Metabolic Coenzymes & Neuropathic/Myopathic Antioxidants (Schedule H / Nutraceutical) for Alpha-Lipoic Acid: Symptomatic diabetic sensorimotor polyneuropathy (600 mg/day reduces burning/lancinating pain scores). Coenzyme Q10: Statin-associated muscle symptoms (SAMS), mitochondrial myopathies, and adjunct in HFrEF (Q-SYMBIO trial). L-Carnitine: Dialysis-related carnitine deficiency/intradialytic muscle cramps, Valproate-induced hepatotoxicity/hyperammonaemia rescue.

4. Therapeutic Indications & Evidence-Supported Uses

  • Alpha-Lipoic Acid: Symptomatic diabetic sensorimotor polyneuropathy (600 mg/day reduces burning/lancinating pain scores)
  • Coenzyme Q10: Statin-associated muscle symptoms (SAMS), mitochondrial myopathies, and adjunct in HFrEF (Q-SYMBIO trial)
  • L-Carnitine: Dialysis-related carnitine deficiency/intradialytic muscle cramps, Valproate-induced hepatotoxicity/hyperammonaemia rescue

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Alpha-Lipoic Acid: 300–600 mg PO Once Daily. Coenzyme Q10: 100–200 mg PO OD–BD. L-Carnitine: 500–1000 mg PO BD–TDS (or 10–20 mg/kg slow IV after each haemodialysis session)

Administration & Meal Timing: OPPOSITE FOOD RULES: (1) Alpha-Lipoic Acid (ALA) should be taken on an EMPTY STOMACH (30 min before breakfast — food and divalent cations [Ca2+, Fe2+, Mg2+] chelate ALA and reduce bioavailability by 30–40%!); (2) Coenzyme Q10 is highly lipophilic and MUST be taken WITH A FAT-CONTAINING MEAL; (3) L-Carnitine is taken with or after meals | ALA: Morning 30m pre-breakfast (or separated from Ca/Fe). CoQ10 & L-Carnitine: With Meals

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Follows class pharmacokinetic profile detailed in parent monograph [10.17].
Metabolism & Biotransformation:
Renal: Safe (in haemodialysis, IV L-Carnitine post-dialysis or low-dose oral 500 mg is preferred). Hepatic: Safe (L-Carnitine is protective in Valproate hepatotoxicity)
Elimination & Renal Adjustment:
Renal: Safe (in haemodialysis, IV L-Carnitine post-dialysis or low-dose oral 500 mg is preferred). Hepatic: Safe (L-Carnitine is protective in Valproate hepatotoxicity)
Hepatic Impairment Considerations:
Renal: Safe (in haemodialysis, IV L-Carnitine post-dialysis or low-dose oral 500 mg is preferred). Hepatic: Safe (L-Carnitine is protective in Valproate hepatotoxicity)

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • ALPHA-LIPOIC ACID INSULIN AUTOIMMUNE SYNDROME (IAS / HIRATA DISEASE) ALERT: Alpha-Lipoic Acid contains sulfhydryl groups that can trigger anti-insulin autoantibodies or directly enhance GLUT-4 glucose uptake, causing spontaneous or postprandial HYPOGLYCAEMIA! Caution with L-Carnitine in seizure disorders

Key Clinical Precautions: Renal: Safe (in haemodialysis, IV L-Carnitine post-dialysis or low-dose oral 500 mg is preferred). Hepatic: Safe (L-Carnitine is protective in Valproate hepatotoxicity)

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • ALA: Mild nausea, epigastric burning, garlic/sulfur-like urine odour. CoQ10: Mild GI upset. L-Carnitine: Nausea, 'fishy' body/urine odour
  • Hypoglycaemia / Insulin Autoimmune Syndrome (Alpha-Lipoic Acid — sweating, tremor, confusion!), seizures (rare with rapid IV L-Carnitine)
Serious / Dose-Limiting Adverse Effects:

    9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

    • CRITICAL ALPHA-LIPOIC ACID INTERACTIONS: (1) Chelates Iron, Calcium, and Magnesium in the gut -> separate ALA by >=2 hours from Iron/Calcium/Antacids!; (2) Potentiates Insulin and Oral Antidiabetics (monitor blood glucose closely!); (3) Space >=4 hours from Levothyroxine! Coenzyme Q10 is structurally similar to Vitamin K2 and can reduce Warfarin INR!

    10. Clinical Monitoring, Patient Counselling & Storage

    Clinical & Laboratory Monitoring: Monitor clinical parameters per parent monograph [10.17].

    Pharmacist Patient Counselling Points:

    • Patient Counselling Checklist: Take Alpha-Lipoic Acid 30 minutes before breakfast (and at least 2 hours away from Iron, Calcium, or Thyronorm) and watch for signs of low blood sugar; take CoQ10 softgels with lunch or dinner
    • Meal & Clock Timing Instruction: OPPOSITE FOOD RULES: (1) Alpha-Lipoic Acid (ALA) should be taken on an EMPTY STOMACH (30 min before breakfast — food and divalent cations [Ca2+, Fe2+, Mg2+] chelate ALA and reduce bioavailability by 30–40%!); (2) Coenzyme Q10 is highly lipophilic and MUST be taken WITH A FAT-CONTAINING MEAL; (3) L-Carnitine is taken with or after meals (ALA: Morning 30m pre-breakfast (or separated from Ca/Fe). CoQ10 & L-Carnitine: With Meals)
    • Missed Dose Protocol: Take at next scheduled slot if missed
    • Geriatric Dispensing Pearl: Monitor blood glucose in older diabetic patients taking ALA-containing neuropathy combinations

    Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Alpha-Lipoic Acid Tablets/Capsules: 100 mg, 300 mg, 600 mg. Coenzyme Q10 Softgels: 100 mg, 200 mg, 300 mg. L-Carnitine Tablets: 500 mg; Oral Solution: 500 mg/5mL; IV: 1 g/5mL

    11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

    THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
    svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

    12. Authoritative References, Regulatory Sources & Editorial Disclaimer

    Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO

    Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

    Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

    Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.